Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

First Posted Date
2012-12-24
Last Posted Date
2018-08-02
Lead Sponsor
Deutsches Herzzentrum Muenchen
Target Recruit Count
1893
Registration Number
NCT01755520
Locations
🇩🇪

Universitätsklinikum Aachen, Aachen, Germany

🇩🇪

Deutsches Herzzentrum München, Munich, Bavaria, Germany

🇦🇹

Klinikum Wels-Grieskirchen, Wels, Austria

and more 26 locations

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

First Posted Date
2012-12-06
Last Posted Date
2014-04-24
Lead Sponsor
AstraZeneca
Target Recruit Count
258
Registration Number
NCT01744288
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

GLP-1 and Microvascular Function in Type 2 Diabetes

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-12-04
Last Posted Date
2017-02-17
Lead Sponsor
Royal Devon and Exeter NHS Foundation Trust
Target Recruit Count
39
Registration Number
NCT01740921
Locations
🇬🇧

Peninsula Clinical Research Facility, Exeter, United Kingdom

Electrophilic Fatty Acid Derivatives in Asthma

First Posted Date
2012-11-27
Last Posted Date
2017-07-11
Lead Sponsor
Sally E. Wenzel MD
Target Recruit Count
50
Registration Number
NCT01733485
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers

First Posted Date
2012-11-20
Last Posted Date
2018-02-19
Lead Sponsor
University Hospital, Tours
Target Recruit Count
1106
Registration Number
NCT01729468
Locations
🇫🇷

Service de Gynécologie-Obstétrique, HFME, Hospices Civils de Lyon, Bron, France

🇫🇷

Service de gynécologie-obstétrique, Polyclinique du PARC, Caen, France

🇫🇷

Service de Gynécologie-Obstétrique, Hôpital d'Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France

and more 14 locations

Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

First Posted Date
2012-10-18
Last Posted Date
2012-10-18
Lead Sponsor
Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales
Target Recruit Count
97
Registration Number
NCT01709994
Locations
🇪🇸

Hospital General Universitario Gregorio Marañon, Madrid, Spain

Aspirin Attenuates Inflammation in Human Cerebral Aneurysms

First Posted Date
2012-10-18
Last Posted Date
2015-05-29
Lead Sponsor
University of Iowa
Target Recruit Count
11
Registration Number
NCT01710072
Locations
🇺🇸

University of Iowa hospitals and Clinics, Iowa CIty, Iowa, United States

Alcohol Inhibits Drug Metabolism by Carboxylesterases

First Posted Date
2012-10-16
Last Posted Date
2012-10-16
Lead Sponsor
University of Tennessee
Target Recruit Count
19
Registration Number
NCT01708369
Locations
🇺🇸

University of Tennessee Health Science Center, Memphis, Tennessee, United States

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

First Posted Date
2012-10-01
Last Posted Date
2018-12-05
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
12
Registration Number
NCT01696760
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath